---
title: "China Resources Pharmaceutical unit issues RMB2 billion corporate bonds"
url: "https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb2-billion-corporate/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-06-26"
section: "Debt Financing"
tickers: "HKEX:3320"
source: "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0626/2026062601849.pdf"
summary: "A non-wholly owned subsidiary completed the third tranche of its 2026 corporate bonds, RMB2 billion at 1.59% per annum over three years."
---

By the aibio.space news desk.

Sources

- [China Resources Pharmaceutical Group Limited announcement (2026-06-26)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0626/2026062601849.pdf)

[3320](https://aibio.space/companies/china-resources-pharmaceutical/)

2026-06-26

# China Resources Pharmaceutical unit issues RMB2 billion corporate bonds

Tickers [3320](https://aibio.space/companies/china-resources-pharmaceutical/)

A non-wholly owned subsidiary completed the third tranche of its 2026 corporate bonds, RMB2 billion at 1.59% per annum over three years.

## Key facts

- **Company**: China Resources Pharmaceutical Group Ltd. (HKEX: 3320)

- **News type**: Debt Financing

- **Primary source**: [China Resources Pharmaceutical Group Limited announcement (2026-06-26)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0626/2026062601849.pdf)

*A city skyline in morning haze. CC0, via rawpixel. The picture shows the field, not the companies named.*

China Resources Pharmaceutical Group Limited said on June 26, 2026 that CR Pharmaceutical Commercial, a non-wholly-owned subsidiary, completed a public issuance of the third tranche of its 2026 corporate bonds in the PRC. The announcement refers to earlier announcements dated 27 March 2026 and 28 April 2026 about the first and second tranches.

The third tranche was issued in a principal amount of RMB2 billion. The bonds have a term of three years and a coupon rate of 1.59% per annum.

The net proceeds will be used for production expenditures, including replenishment of working capital, repayment of interest-bearing debts, project investments and other purposes that comply with applicable laws and regulations.

The announcement names no underwriter, placement agent or advisor for the tranche. Shareholders and potential investors were told to take care when dealing in the company's securities. The announcement was issued by order of the board and signed by the chairman, Mr. Bai Xiaosong.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

3320

China Resources Pharmaceutical Group Ltd.

HKEX · Hong Kong

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb2-billion-corporate/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "China Resources Pharmaceutical unit issues RMB2 billion corporate bonds", 2026-06-26, https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb2-billion-corporate/